Egypt’s brand-name prescriptions turn ordinary dispensing into a safety trap

An error that endangered a child has reopened a long-running argument inside Egypt’s medicine system: doctors commonly prescribe brand names, leaving pharmacists and patients to navigate products whose names may resemble one another while their active ingredients or concentrations differ. Mada Masr’s reporting follows pharmacists calling for prescriptions to identify the scientific substance instead.

Prescribing the active ingredient would make equivalent products easier to recognize, while keeping the dose and formulation explicit.

That change would not eliminate error. Handwriting, dosage, formulation and pharmacy workload still matter. But it would make the prescription itself a clearer specification, particularly during shortages when the named product is unavailable. It could also weaken the commercial advantage created when one company’s label becomes synonymous with the medicine.

Safety failures are often blamed on the last person in the chain. This story instead asks whether the chain is designed to fail gracefully. A standardized ingredient-first prescription, backed by electronic checks and clear substitution rules, would make mistakes easier to catch before they reach the patient.